Navigation Links
Technologies to Enhance Cell Line Productivity and Expand Antibody-Drug Conjugate Therapeutic Window to be Presented by Catalent Biologics at PEGS
Date:8/26/2020

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that two Catalent Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020.

On Wednesday, Sept. 2 at 9:45 a.m. EDT, Gregory Bleck, Ph.D., Global Head of R&D, Catalent Biologics, will present “GPEx® Boost – A Novel Approach for High-Expressing CHO Cell Line Engineering” during the “Optimizing Protein Expression” stream. Dr. Bleck will explain how the next generation of Catalent’s GPEx cell line development technology can result in highly specific productivities, titers, and improved cell growth characteristics for most protein products.

Also on Wednesday, at 3:05 p.m. EDT, during the “Engineering Antibody-Drug Conjugates” stream, Robyn Barfield, Ph.D., Group Leader, Catalent Biologics, will discuss Catalent’s proprietary SMARTag® technology, which uses a simple, robust manufacturing process to generate stable, site-specific antibody-drug conjugates (ADCs). In her presentation, titled “Novel SMARTag Linkers Enable Better-Tolerated ADCs,” Dr. Barfield will discuss how the technology can offer wider therapeutic windows, illustrated through a comparison between Catalent’s anti-HER2 RED-106 ADC, and the related drug, T-DM1.

During the virtual event, Dr. Barfield will also present the case study in her presentation as a poster, “A Novel HER2-Targeted Antibody-Drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-Equivalent Exposure Levels.”

Dr. Bleck has more than 20 years of experience in biopharmaceutical research and development. He has a bachelor’s degree and doctorate from the University of Wisconsin-Madison and performed postdoctoral work at the University of Illinois-Urbana-Champaign, working in the areas of gene regulation and expression. At Catalent, Dr. Bleck has transferred his knowledge of gene expression and transgenic systems to the development and continued optimization of retrovector expression systems and development of the proprietary GPEx process.

Dr. Barfield has more than 10 years’ experience working in bioconjugation, and joined Catalent Biologics when it acquired Redwood Bioscience in 2014. She has a doctorate in cell and molecular biology from the University of Pennsylvania School of Medicine and a bachelor’s degree in genetics and cell biology, from the University of Georgia.

The event’s presentations and panel discussions will be available to view on-demand through the conference platform. For more information about the event, please visit biologics.catalent.com/events/pegs-boston/

Catalent, GPEx and SMARTag are registered trademarks of Catalent, Inc. or its affiliates or subsidiaries.

About Catalent Biologics

Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx® cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/technologies_to_enhance_cell_line_productivity_and_expand_antibody_drug_conjugate_therapeutic_window_to_be_presented_by_catalent_biologics_at_pegs/prweb17346332.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19
2. F. Hoffmann La Roche and Johnson & Johnson license patented drug-discovery platform technologies from Housey Pharma
3. Oxford Nanopore Technologies announces advanced development of LamPORE, for rapid, highly scalable, low-cost COVID-19 detection
4. Brevitest Technologies Becomes First Remote Resident of Baltimore’s LaunchPort™ Manufacturing Accelerator
5. Lifecycle Biotechnologies Introduces High Purity Powder Chemicals Capabilities
6. Lifecycle Biotechnologies Releases 2020 Company Prospectus
7. Lifecycle Biotechnologies Completes Full Integration of Chata Biosystems and VI Plastics
8. Lifecycle Biotechnologies launches second generation CHEM+POUR Bag
9. Innovative Surgical Robotics Technologies for Spine Surgery to Become the Standard, Not the Exception
10. Worldwide Business with kathy ireland®: See Helius Medical Technologies Introduce How They're Pioneering Portable Neurostimulation
11. SIGGRAPH 2019: Lemnis Technologies Unveils Verifocal™ Mixed Reality Headsets with New Generation Eye Tracker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received ... innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be assigned ... syringe. The company’s solutions are the first Wharton’s jelly allograft product to be recognized ...
(Date:7/22/2020)... , ... July 21, 2020 , ... ... transformation and innovation in technology and compliance, announces a new solution to manage ... must ensure every layer of their technology stack complies with FDA and global ...
(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient MasterClass ... is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of savory ... at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting & ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... RIDING, Va. (PRWEB) , ... September 01, 2020 ... ... firm for life sciences, biotechnology, and diagnostics companies, has announced the placement of ... . Averill will be responsible for leading all financial operations and implementing key ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society ... Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of ... a consortium of academic research centers in the United States and Europe with ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... announced Jim Corrigan, President and CEO has been named one of the 100 ... of industry sectors, PharmaVoice 100 honorees are selected based on how they have ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... solid-state radar transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, ... that can drive one or two switches in a push-pull configuration; yielding fast ...
Breaking Biology Technology: